Onxx

BigNick

Siamo solo noi
Registrato
10/7/01
Messaggi
11.738
Punti reazioni
1.140
ONXX

Questo è il titolino che mi stuzzica, premetto che trattasi di titolo “MOLTO RISCHIOSO”, quindi valutare bene prima di entrare, e fissare uno stop adeguato, ultimamente è venuto su bene, potrebbe essere solo speculazione in attesa della conferenza ASCO che si terrà il 31 di Maggio, oppure potrebbe essere qualcosa di concreto relativo al business dell’azienda “Terapie contro il cancro”.
Volevo entrare ieri, ma ho perso l’attimo e me la sono ritrovata a + 15%, oggi potrebbe ritracciare e magari ci metto una zampina, reputo interessante un entrata intorno ai 9,4 / 9,6, pero’ aspetto i vostri contributi: mi raccomando non fatevi pregare !!

Sono graditi , Commenti sui fondamentali,News, Pareri grafici, movimenti di book, tutto quanto ci possa aiutare a decidere eventuali entrate o uscite, personalmente se ci entro, entro con poco per ridurre al minimo ogni rischio

BigNIck

ONXX

HomePage: www.onyx-pharm.com.

Business Summary

Onyx Pharmaceuticals, Inc. is engaged in the discovery and development of novel cancer therapies utilizing two technology platforms, small molecules that inhibit the proteins involved in excess growth signaling, and therapeutic viruses that selectively replicate in cells with cancer-causing genetic mutations. The Company is developing a novel small molecule compound, BAY 43-9006, in collaboration with Bayer Pharmaceuticals Corporation. Utilizing its proprietary virus technology, the Company is developing ONYX-411, a second-generation product that targets cancers with abnormal function of the retinoblastoma tumor-suppressor gene, and is developing Armed Therapeutic Virus products.
More from Multex: Expanded Business Description


Ultima Semestrale:
Onyx Reports First Quarter 2003 Financial Results
Thursday May 1, 4:06 pm ET
RICHMOND, Calif., May 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) reported a net loss of $10.7 million, or $0.47 per share for the quarter ended March 31, 2003, compared to a net loss of $9.8 million, or $0.53 per share for the same quarter in 2002. These results reflect higher clinical development expenditures for Onyx's lead product, BAY 43-9006, an orally active small molecule anticancer compound in codevelopment with Bayer Pharmaceuticals Corporation, partially offset by reduced expenditures in the company's therapeutic virus program. The expenses also include $0.4 million in restructuring costs related to the quarter's reduction in force and a one-time $1.0 million milestone due XOMA (US) LLC for successful achievement of virus manufacturing objectives. In January 2003, the company announced that it was reducing staff by 25 percent to conserve capital and to reflect both an increased priority on the development of BAY 43-9006 and a suspension of clinical trials of ONYX-015.
The company indicated that without the one-time restructuring charge of $0.4 million and the milestone payment of $1.0 million in the quarter, the results would show a non-GAAP net loss of $9.2 million as compared to the U.S. GAAP net loss of $10.7 million. Onyx explained that, on a non-GAAP basis, this represents a $4.1 million reduction from the $13.3 million net loss reported for the fourth quarter of 2002 and is consistent with the guidance provided after the January 2003 restructuring. The company also noted that the GAAP net loss of $10.7 million in the current quarter represents a $2.6 million reduction from the net loss in the fourth quarter of 2002.
As of March 31, 2003, the company had cash, cash equivalents and marketable securities of $37.7 million compared to $39.8 million at December 31, 2002. In February 2003, the company raised $10.0 million in a private placement of 2,105,263 shares of its common stock at $4.75 per share, primarily to Deerfield Management Company, Inc.
For the quarter ended March 31, 2003, Onyx reported no revenue as compared to total revenue of $0.8 million for the same quarter a year ago when Onyx still received research funding from Warner-Lambert Company, a subsidiary of Pfizer, Inc, for the now-terminated therapeutic virus collaboration.
Onyx Pharmaceuticals is engaged in the discovery and development of novel cancer therapies and has proprietary technologies that target the molecular basis of cancer. The company is developing small molecule drugs, including BAY 43-9006 in codevelopment with Bayer. In addition, the company's preclinical portfolio includes proprietary therapeutic viruses and Armed Therapeutic Virus(TM) products. For more information about Onyx's pipeline and activities, visit the company's website at www.onyx-pharm.com.


<
 
Montly

.
 

Allegati

  • m1.gif
    m1.gif
    28,7 KB · Visite: 320
Weekly

.
 

Allegati

  • w1.gif
    w1.gif
    31,6 KB · Visite: 326
Daily

.
 

Allegati

  • d1.gif
    d1.gif
    25,9 KB · Visite: 314
Non posso postare il grafico ma ieri a fatto un candelone che potrebbe preannunciare una bandiera, possibile sosta intorno agli 11....
 
i principali competitor--biotech in fermento.

VRAONXX



View Competitors

ONYX Pharmaceuticals, Inc. NASDAQ-NM

Competitor : Major Pharmaceuticals The following table is sorted by Market Capitalization in descending order. Click on the column header links to resort ascending () or descending ().




Company Name
Symbol : Market Last
Sale Net
Change %
Change Share
Volume Today's
High/Low 52 Week
High/Low P/E
Ratio Market
Value
(mil.)
ONYX Pharmaceuticals, Inc.
ONXX : NASDAQ-NM $ 10.58 1.42 15.5% 832,026 $ 10.65
$ 9.11 $ 10.65
$ 3.15 NE 217.37

--------------------------------------------------------------------------------

PFIZER INC
PFE : NYSE $ 32.16 0.66 2.1% 24,261,400 $ 32.44
$ 31.51 $ 37.28
$ 25.13 20.59 251,125.81

--------------------------------------------------------------------------------

MERCK & CO INC
MRK : NYSE $ 55.55 0.17 0.31% 6,402,700 $ 56.06
$ 54.90 $ 60.48
$ 38.50 17.36 124,358.89

--------------------------------------------------------------------------------

GLAXOSMITHKLINE PLC
GSK : NYSE $ 41.40 0.70 1.72% 577,600 $ 41.66
$ 40.67 $ 48
$ 31.35 N/A 122,704.76

--------------------------------------------------------------------------------

ASTRAZENECA PLC
AZN : NYSE $ 41.75 0.83 2.03% 1,720,300 $ 41.95
$ 40.66 $ 47.71
$ 28 25.1 70,300.56

--------------------------------------------------------------------------------

ELI LILLY & CO
LLY : NYSE $ 57.73 0.57 0.98% 5,742,100 $ 58.30
$ 57.24 $ 69.70
$ 43.75 25.35 65,492.70

--------------------------------------------------------------------------------

ABBOTT LABORATORIES
ABT : NYSE $ 41.95 0.55 1.33% 3,734,600 $ 42.55
$ 41.41 $ 48.05
$ 29.80 23.66 64,725.51

--------------------------------------------------------------------------------

WYETH
WYE : NYSE $ 42.07 0.37 0.89% 4,752,500 $ 42.50
$ 41.39 $ 59.27
$ 28.25 11.46 55,279.65

--------------------------------------------------------------------------------

BRISTOL MYERS SQUIBB CO
BMY : NYSE $ 24.26 0.27 1.13% 5,411,300 $ 24.55
$ 24 $ 31.70
$ 19.49 22.85 46,469.71

--------------------------------------------------------------------------------

AVENTIS SA
AVE : NYSE $ 52.08 0.19 0.37% 199,900 $ 52.19
$ 51.25 $ 72.06
$ 41.85 14.95 41,484.76

--------------------------------------------------------------------------------

E I DU PONT DE NEMOURS & CO
DD : NYSE $ 40.90 0.08 0.2% 2,952,900 $ 41.17
$ 40.60 $ 47.48
$ 34.71 21.26 40,604.06

--------------------------------------------------------------------------------

SCHERING PLOUGH CORP
SGP : NYSE $ 17.75 0.24 1.37% 5,103,900 $ 17.86
$ 17.41 $ 27.23
$ 15.22 16.68 25,680.69

--------------------------------------------------------------------------------

FOREST LABORATORIES INC
FRX : NYSE $ 49.64 1.03 2.12% 2,048,700 $ 50.18
$ 48.55 $ 57.13
$ 32.13 29.11 17,645.58

--------------------------------------------------------------------------------

SCHERING AG
SHR : NYSE $ 51.03 0.53 1.05% 6,100 $ 51.10
$ 50.16 $ 63.60
$ 34.16 N/A 9,999.00

--------------------------------------------------------------------------------

Gilead Sciences, Inc.
GILD : NASDAQ-NM $ 47.43 1.78 3.9% 2,922,615 $ 47.65
$ 45.59 $ 49.02
$ 26.08 NE 9,061.71

--------------------------------------------------------------------------------

Teva Pharmaceutical Industries Limited
TEVA : NASDAQ-NM $ 48.25 1.30 2.77% 2,370,447 $ 48.26
$ 46.60 $ 48.65
$ 28.57 27.62 8,774.25

--------------------------------------------------------------------------------

SERONO SA
SRA : NYSE $ 13.99 0.39 2.87% 306,800 $ 14.02
$ 13.60 $ 20.45
$ 10.25 28.33 8,738.82

--------------------------------------------------------------------------------

BIOVAIL CORP
BVF : NYSE $ 45.46 1.77 4.05% 1,859,200 $ 45.81
$ 43.55 $ 45.81
$ 19.90 70.47 6,968.25

--------------------------------------------------------------------------------

MYLAN LABORATORIES INC
MYL : NYSE $ 29.10 0.61 2.14% 1,515,100 $ 29.34
$ 28.61 $ 30.47
$ 17.40 19.51 5,236.23

--------------------------------------------------------------------------------

IDEC Pharmaceuticals Corporation
IDPH : NASDAQ-NM $ 35 1.70 5.11% 3,551,733 $ 35.20
$ 33.30 $ 48.18
$ 20.76 36.2 5,164.03

--------------------------------------------------------------------------------

WATSON PHARMACEUTICALS INC
WPI : NYSE $ 36.25 0.67 1.88% 1,914,500 $ 36.55
$ 35.40 $ 36.80
$ 17.95 19.99 3,804.96



Page 1 of 9 (20 per page)
Next
1 2 3 4 5 6 7 8 9



© Copyright | Disclaimer | Trademarks | Privacy Statement | Contact Us | Help | Search
 
In questi ultimi giorni l'interesse per ' farmaceutici/biotech' in effetti è molto alto.

TGEN ne è un esempio (anche se il giorno successivo ha ritracciato)

Per ONXX il grafico, anche prima dell'ascesa di ieri, mi pare ben impostato.

SL = 9,06
TP = 12,17
 
Non male....allego grafico (MA) 60 min
 

Allegati

  • onxx.jpg
    onxx.jpg
    117 KB · Visite: 297
chi riesce a postare il book del pre ?

.
 
beh ?

dove tutta sta collaborazione ?

delusi ?

Luciano molla un attimo le dentiere e dimmi la tua :D

BigNick
 
le ho messe nella lista delle sorvegliate speciali,certo che e' rischiosetta :D ma del resto chi non risica......vediamo :)
 
non è che state collaborando troppo eh ??

sfaticati !! :D

entrato con 500 pezzi, queste sembrano che non hanno voglia di scendere, azzz erano da prendere ieri

BigNIck
 
Entrato oggi con 240 pezzi a 10.68. Non male come primo giorno. Grazie Big. Pero' ti sei perso la mia segnalazione su ONCY ( ha fatto il 150% in meno di una settimana ).
 
r

Scritto da valsente
Entrato oggi con 240 pezzi a 10.68. Non male come primo giorno. Grazie Big. Pero' ti sei perso la mia segnalazione su ONCY ( ha fatto il 150% in meno di una settimana ).

ONCY l'avevo notata ma non è in OTC ?
 
chi c'è dentro ?

speriamo abbia finito di stornare

BigNick
 

Allegati

  • 1dm.gif
    1dm.gif
    30,5 KB · Visite: 139
Mi stavo dimenticando di ONXX

10,9 16:25:22 7,92%


Novel RAF Kinase Inhibitor Bay 43-9006 Shows Early Signs of Tolerability and Activity in Phase Ib Combination Trials Reported at ASCO
Monday, June 2, 2003 10:00 AM ET Printer-friendly version

Final Data from Phase I Single-Agent Studies also Presented
WEST HAVEN, Conn. and RICHMOND, Calif, June 2 /PRNewswire-FirstCall/ -- Bayer Pharmaceuticals Corporation (NYSE: BAY, news) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX, news) today announced at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago encouraging Phase Ib data from two clinical trials of BAY 43-9006, a novel, investigational RAF kinase inhibitor, in combination with standard chemotherapeutics, as well as final Phase I results that confirm and extend the positive findings presented at international medical meetings in 2002. This novel inhibitor is an orally active small molecule agent currently in Phase II clinical development in a collaboration between Bayer and Onyx. The data describe safety findings and preliminary antitumor activity from multiple Phase Ib chemotherapy combination trials and Phase I single-agent clinical trials.



Phase Ib Clinical Study: BAY 43-9006 in Combination with Gemcitabine (Abstract 828)

Safety, pharmacokinetics and tumor response rate from a multicenter Phase Ib study of BAY 43-9006 in combination with gemcitabine were presented today in a poster presentation by Lillian L. Siu, M.D., of Princess Margaret Hospital in Toronto, Canada. The study was a dose-escalating Phase Ib trial, in which BAY 43-9006 was administered continuously at three different dose levels up to 400 mg twice daily, along with gemcitabine given at the standard dose of 1000 mg/m2. The patients had advanced solid tumors including pancreatic, colorectal, ovarian, esophageal, gastric, liposarcoma, nasopharyngeal and mesothelioma, for which no standard therapy exists and who were deemed suitable for treatment with gemcitabine chemotherapy. The safety results were reported in 20 patients treated on study. Hematological toxicities observed in the clinical data were non-dose limiting and consistent with gemcitabine effects. Non-hematological toxicities included decreased appetite, fatigue, hand-foot syndrome, skin rash, nausea and diarrhea. Only fatigue proved dose-limiting in one patient treated at the highest dose. Preliminary pharmacokinetic analysis revealed no significant interactions between BAY 43-9006 and gemcitabine. Data from 20 patients included one patient with a confirmed partial response in previously treated ovarian cancer, and disease stabilization of eight weeks or more in 11 patients with tumor types including: ovarian, pancreatic, colorectal, nasopharyngeal, and an unknown primary tumor. An expanded cohort of pancreatic cancer patients is currently being evaluated in this study.


Phase Ib Clinical Study: BAY 43-9006 in Combination with Carboplatin and Paclitaxel (Abstract 2854)

Data from a second chemotherapy combination Phase Ib study of BAY 43-9006 were presented Saturday, May 31, at an ASCO session devoted to melanoma and described in an announcement issued that day by the University of Pennsylvania. The multicenter, dose-escalating trial was designed to evaluate different dosage levels of BAY 43-9006 administered in combination with carboplatin and paclitaxel. Thus far, 20 patients with a variety of tumor types have been treated in the study. In an oral presentation, Keith T. Flaherty, M.D., of the University of Pennsylvania reported that BAY 43-9006 was well tolerated when combined with full dose carboplatin and paclitaxel. Toxicities, including skin rash and hand-foot syndrome, resolved themselves. No pharmacokinetic interaction between BAY 43-9006 and paclitaxel or carboplatin was reported. Dr. Flaherty reported confirmed partial responses in three of ten evaluable patients with melanoma, and disease stabilization in six additional melanoma patients, four of whom showed evidence of tumor necrosis.

"These trials are two of eight ongoing studies evaluating BAY 43-9006 in combination with a range of standard chemotherapeutic agents," stated Susan Kelley, M.D., Vice President of Oncology Product Development at Bayer Pharmaceuticals. "Further evaluation of BAY 43-9006 administered in combination with these cytotoxic drugs is warranted, based on these preliminary data. We are encouraged by the non-overlapping toxicity profiles and early indications of activity in the clinical setting."


Phase I Clinical Trials: Single-Agent BAY 43-9006 (Abstract 793)


Final data from single-agent Phase I clinical trials of BAY 43-9006 were presented today in a poster session by Dirk Strumberg, M.D., of the West German Cancer Center at the University of Essen. This report included data from four clinical Phase I single agent studies conducted at the University of Essen, the Jules Bordet Institute in Belgium, the Hamilton Regional Cancer Centre and Princess Margaret Hospital in Canada, and the Dana Farber Cancer Institute and the University of Southern California in the United States. In an analysis of 118 patients with advanced malignancies who received BAY 43-9006 doses of 200 mg twice daily or higher, 29 patients remained on BAY 43-9006 for more than six months, with no tumor progression or serious treatment-related adverse events. Of these, nine were on treatment for more than one year, with no disease progression or serious treatment-related adverse events. Durable partial responses were also observed in one liver cancer patient and one kidney cancer patient. Most of the dose-limiting toxicities were seen at dose levels of 600 mg twice daily or greater and included diarrhea and skin toxicity.

"These results from our now-completed single-agent Phase I program for BAY 43-9006 show signs of a favorable safety profile and preliminary antitumor activity," stated Dr. Kelley. "Phase II clinical trials are ongoing, and we are making preparations for the start of phase III."


About BAY 43-9006


BAY 43-9006 is a novel investigational compound directed against a specific molecular target involved in excess growth signaling in cancer. BAY 43-9006 blocks the enzyme RAF kinase, which is a critical component of the RAS pathway -- an important cascade of chemical signals that control cell division. Activating mutations of a RAS gene are estimated to occur in almost one-third of human cancers, including 90 percent of pancreatic cancer, 50 percent of colon cancer and 30 percent of non-small cell lung cancer. In addition, recent research suggests that a specific RAF kinase, BRAF, is activated by mutation in two-thirds of melanomas and smaller percentages of several other cancers.

The codevelopment collaboration between Onyx and Bayer results in Onyx funding 50 percent of the development costs for BAY 43-9006. In return, Onyx has a 50/50 profit share in the United States, where the companies can co-promote the product. Everywhere else in the world except Japan, Onyx's share is somewhat less than 50 percent since Bayer has exclusive marketing rights. In Japan, Bayer funds product development, and Onyx receives a royalty.


About Onyx Pharmaceuticals
 
Early Study Results Promising: Oral Medication Active Against SkinCancer

CHICAGO, Jun 02, 2003 (ASCRIBE NEWS via COMTEX) -- Researchers from the Abramson Cancer Center of the University of Pennsylvania today presented early study results showing that a new kind of drug, a Raf kinase inhibitor, is well tolerated and may prove effective in treating patients with metastatic melanoma, the most severe form of skin cancer. Standard chemotherapy has limited effectiveness against metastatic melanoma (i.e. dacarbazine).

The findings were released by co-Principal Investigators Keith Flaherty, MD, and Peter O'Dwyer, MD, at the 39th Annual Meeting of the American Society for Clinical Oncology, taking place in Chicago, May 31 to June 3. Early results from a Phase I clinical study show that the Raf kinase inhibitor produced promising anti-cancer activity in patients with metastatic (or widespread) melanoma: Seven out of ten patients tested showed benefit that lasted up to ten months. The investigational drug, named BAY43-9006, is a pill therapy under development by Bayer and Onyx Pharmaceuticals.

"It is promising to see patients do so well, this early in the research," said Flaherty, Instructor of Medicine at the Abramson Cancer Center of the University of Pennsylvania. "Melanoma is a disease that does not frequently respond to current therapies."

Raf kinase inhibitors are small molecules that prevent or interrupt the action of Raf kinase, a key enzyme in the chain reaction of the body's chemistry that triggers cell growth. Abnormal activation of this pathway is a common thread in the development of most cancers, including two-thirds of melanomas. By blocking the action of Raf kinase, scientists hope they can reverse the progression of these tumors.

Twenty patients were enrolled in the first part of the Phase I study, which began in April 2002. The Phase I trial was funded through a research grant from Bayer Pharmaceuticals.

The primary goal of the Phase I trial is to determine a safe dosage of the Raf kinase inhibitor for use in future studies. Patients were given the Raf kinase inhibitor, twice daily - in varying doses of either 100 mg, 200 mg, or 400 mg - for a period of three weeks, in combination with two standard cancer therapies, carboplatin and paclitaxel.

The safety profile of the combination therapy was determined as favorable, with minimal and reversible side effects, such as rash and diarrhea.

"With this study, we have confirmed that the Raf kinase inhibitor can be used safely in conjunction with other standard cancer therapies," said O'Dwyer, Director of the Developmental Therapeutics Program and Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania. "Associated laboratory studies show that the Raf kinase inhibitor, at these doses, blocks the target pathway. Our next step is to continue to investigate this further in order to develop effective therapies for this life-threatening disease."

For 2003, the American Cancer Society estimates that over 54,000 Americans (2,700 Pennsylvanians) will be diagnosed with melanoma and 7,600 will die from the disease.

Note: Neither Drs.Flaherty or O'Dwyer have any financial interest in Bayer or Onyx Pharmaceuticals.
 
Scritto da Luciano
ciao Big


oggi in batteria dopo un bel viaggetto


in piedi dalle 4 3 ore di macchina e 300 chilometri ora mi attendono 15 ore di lavoro e la borsona tanto per tenere l'adrenalina a livelli ottimali:D


ciao

mi sembra giusto dopo ben 1 giorno di ferie, sarebbe anche il caso di tornare a lavorare !!

BigNIck:D :D
 
In after ieri qualcuno si è portato via 25.000 pezzi a 10.36

17:18:02 10.160 100 Pacific
17:09:41 10.160 100 Cincinnati at Ask
16:11:27 10.360 25000 Nasdaq-NM
16:02:02 10.190 100 Nasdaq-NM
16:02:02 10.190 200 Nasdaq-NM
16:02:02 10.190 800 Nasdaq-NM
16:02:01 10.190 200 Nasdaq-NM
15:59:38 10.180 100 Nasdaq-NM
15:59:38 10.200 600 Nasdaq-NM at Ask
15:59:36 10.200 800 Nasdaq-NM at Ask
 
Indietro